Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

Page: 131

Published Date: 24 Feb 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

The global Hepatocellular Carcinoma Targeted Drug market size is expected to reach $ 1439.2 million by 2030, rising at a market growth of 7.5% CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).

This report studies the global Hepatocellular Carcinoma Targeted Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Hepatocellular Carcinoma Targeted Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hepatocellular Carcinoma Targeted Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Hepatocellular Carcinoma Targeted Drug total market, 2019-2030, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Hepatocellular Carcinoma Targeted Drug total market, key domestic companies and share, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug revenue by player and market share 2019-2024, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Type, CAGR, 2019-2030, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Hepatocellular Carcinoma Targeted Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma and CSPC, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hepatocellular Carcinoma Targeted Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Hepatocellular Carcinoma Targeted Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Type
Sorafenib
Lenvatinib
Regorafenib
Other

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Application
Hospital
Retail Pharmacy
Other

Companies Profiled:
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere

Key Questions Answered
1. How big is the global Hepatocellular Carcinoma Targeted Drug market?
2. What is the demand of the global Hepatocellular Carcinoma Targeted Drug market?
3. What is the year over year growth of the global Hepatocellular Carcinoma Targeted Drug market?
4. What is the total value of the global Hepatocellular Carcinoma Targeted Drug market?
5. Who are the major players in the global Hepatocellular Carcinoma Targeted Drug market?
btl

Table of Contents

1 Supply Summary
1.1 Hepatocellular Carcinoma Targeted Drug Introduction
1.2 World Hepatocellular Carcinoma Targeted Drug Market Size & Forecast (2019 & 2023 & 2030)
1.3 World Hepatocellular Carcinoma Targeted Drug Total Market by Region (by Headquarter Location)
1.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Region (2019-2030), (by Headquarter Location)
1.3.2 United States Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.3 China Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.4 Europe Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.5 Japan Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.6 South Korea Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.7 ASEAN Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.8 India Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Hepatocellular Carcinoma Targeted Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Hepatocellular Carcinoma Targeted Drug Major Market Trends

2 Demand Summary
2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region
2.2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2019-2024)
2.2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2025-2030)
2.3 United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.4 China Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.5 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.6 Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.7 South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.8 ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.9 India Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)

3 World Hepatocellular Carcinoma Targeted Drug Companies Competitive Analysis
3.1 World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2019-2024)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug in 2023
3.2.3 Global Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug in 2023
3.3 Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
3.4 Hepatocellular Carcinoma Targeted Drug Market: Overall Company Footprint Analysis
3.4.1 Hepatocellular Carcinoma Targeted Drug Market: Region Footprint
3.4.2 Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
3.4.3 Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
4.1.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
4.2 United States Based Companies VS China Based Companies: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison
4.2.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
4.3 United States Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2019-2024
4.3.1 United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)
4.4 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue and Market Share, 2019-2024
4.4.1 China Based Hepatocellular Carcinoma Targeted Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)
4.5 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2019-2024
4.5.1 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)

5 Market Analysis by Type
5.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Sorafenib
5.2.2 Lenvatinib
5.2.3 Regorafenib
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2019-2024)
5.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2025-2030)
5.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
6.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2024)
6.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2025-2030)
6.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2030)

7 Company Profiles
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
7.1.4 Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Eisai
7.2.1 Eisai Details
7.2.2 Eisai Major Business
7.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
7.2.4 Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.2.5 Eisai Recent Developments/Updates
7.2.6 Eisai Competitive Strengths & Weaknesses
7.3 Zelgen
7.3.1 Zelgen Details
7.3.2 Zelgen Major Business
7.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
7.3.4 Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.3.5 Zelgen Recent Developments/Updates
7.3.6 Zelgen Competitive Strengths & Weaknesses
7.4 Cipla
7.4.1 Cipla Details
7.4.2 Cipla Major Business
7.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
7.4.4 Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.4.5 Cipla Recent Developments/Updates
7.4.6 Cipla Competitive Strengths & Weaknesses
7.5 Natco Pharma
7.5.1 Natco Pharma Details
7.5.2 Natco Pharma Major Business
7.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.5.4 Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.5.5 Natco Pharma Recent Developments/Updates
7.5.6 Natco Pharma Competitive Strengths & Weaknesses
7.6 BEACON Pharma
7.6.1 BEACON Pharma Details
7.6.2 BEACON Pharma Major Business
7.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.6.4 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.6.5 BEACON Pharma Recent Developments/Updates
7.6.6 BEACON Pharma Competitive Strengths & Weaknesses
7.7 Jiangxi Shanxiang
7.7.1 Jiangxi Shanxiang Details
7.7.2 Jiangxi Shanxiang Major Business
7.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
7.7.4 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.7.5 Jiangxi Shanxiang Recent Developments/Updates
7.7.6 Jiangxi Shanxiang Competitive Strengths & Weaknesses
7.8 Yao Pharma
7.8.1 Yao Pharma Details
7.8.2 Yao Pharma Major Business
7.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.8.4 Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.8.5 Yao Pharma Recent Developments/Updates
7.8.6 Yao Pharma Competitive Strengths & Weaknesses
7.9 CSPC
7.9.1 CSPC Details
7.9.2 CSPC Major Business
7.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
7.9.4 CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.9.5 CSPC Recent Developments/Updates
7.9.6 CSPC Competitive Strengths & Weaknesses
7.10 CHIATAI Tianqing
7.10.1 CHIATAI Tianqing Details
7.10.2 CHIATAI Tianqing Major Business
7.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
7.10.4 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.10.5 CHIATAI Tianqing Recent Developments/Updates
7.10.6 CHIATAI Tianqing Competitive Strengths & Weaknesses
7.11 Simcere
7.11.1 Simcere Details
7.11.2 Simcere Major Business
7.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
7.11.4 Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.11.5 Simcere Recent Developments/Updates
7.11.6 Simcere Competitive Strengths & Weaknesses

8 Industry Chain Analysis
8.1 Hepatocellular Carcinoma Targeted Drug Industry Chain
8.2 Hepatocellular Carcinoma Targeted Drug Upstream Analysis
8.3 Hepatocellular Carcinoma Targeted Drug Midstream Analysis
8.4 Hepatocellular Carcinoma Targeted Drug Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
Table 2. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
Table 3. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
Table 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019-2024), (by Headquarter Location)
Table 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2025-2030), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Hepatocellular Carcinoma Targeted Drug Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
Table 8. World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 9. World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2025-2030) & (USD Million)
Table 10. World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2019-2024) & (USD Million)
Table 11. Revenue Market Share of Key Hepatocellular Carcinoma Targeted Drug Players in 2023
Table 12. World Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Player, Based on Revenue in 2023
Table 13. Global Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
Table 14. Head Office of Key Hepatocellular Carcinoma Targeted Drug Player
Table 15. Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
Table 16. Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
Table 17. Hepatocellular Carcinoma Targeted Drug Mergers & Acquisitions Activity
Table 18. United States VS China Hepatocellular Carcinoma Targeted Drug Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 19. United States VS China Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 20. United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 22. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 23. China Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 25. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 26. Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 28. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
Table 30. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2019-2024) & (USD Million)
Table 31. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2025-2030) & (USD Million)
Table 32. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
Table 33. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2024) & (USD Million)
Table 34. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2025-2030) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
Table 38. Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Eisai Basic Information, Area Served and Competitors
Table 42. Eisai Major Business
Table 43. Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
Table 44. Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 45. Eisai Recent Developments/Updates
Table 46. Eisai Competitive Strengths & Weaknesses
Table 47. Zelgen Basic Information, Area Served and Competitors
Table 48. Zelgen Major Business
Table 49. Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
Table 50. Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 51. Zelgen Recent Developments/Updates
Table 52. Zelgen Competitive Strengths & Weaknesses
Table 53. Cipla Basic Information, Area Served and Competitors
Table 54. Cipla Major Business
Table 55. Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
Table 56. Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 57. Cipla Recent Developments/Updates
Table 58. Cipla Competitive Strengths & Weaknesses
Table 59. Natco Pharma Basic Information, Area Served and Competitors
Table 60. Natco Pharma Major Business
Table 61. Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 62. Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 63. Natco Pharma Recent Developments/Updates
Table 64. Natco Pharma Competitive Strengths & Weaknesses
Table 65. BEACON Pharma Basic Information, Area Served and Competitors
Table 66. BEACON Pharma Major Business
Table 67. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 68. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 69. BEACON Pharma Recent Developments/Updates
Table 70. BEACON Pharma Competitive Strengths & Weaknesses
Table 71. Jiangxi Shanxiang Basic Information, Area Served and Competitors
Table 72. Jiangxi Shanxiang Major Business
Table 73. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
Table 74. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 75. Jiangxi Shanxiang Recent Developments/Updates
Table 76. Jiangxi Shanxiang Competitive Strengths & Weaknesses
Table 77. Yao Pharma Basic Information, Area Served and Competitors
Table 78. Yao Pharma Major Business
Table 79. Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 80. Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 81. Yao Pharma Recent Developments/Updates
Table 82. Yao Pharma Competitive Strengths & Weaknesses
Table 83. CSPC Basic Information, Area Served and Competitors
Table 84. CSPC Major Business
Table 85. CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
Table 86. CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 87. CSPC Recent Developments/Updates
Table 88. CSPC Competitive Strengths & Weaknesses
Table 89. CHIATAI Tianqing Basic Information, Area Served and Competitors
Table 90. CHIATAI Tianqing Major Business
Table 91. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
Table 92. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 93. CHIATAI Tianqing Recent Developments/Updates
Table 94. Simcere Basic Information, Area Served and Competitors
Table 95. Simcere Major Business
Table 96. Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
Table 97. Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 98. Global Key Players of Hepatocellular Carcinoma Targeted Drug Upstream (Raw Materials)
Table 99. Hepatocellular Carcinoma Targeted Drug Typical Customers
List of Figure
Figure 1. Hepatocellular Carcinoma Targeted Drug Picture
Figure 2. World Hepatocellular Carcinoma Targeted Drug Total Market Size: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Hepatocellular Carcinoma Targeted Drug Total Market Size (2019-2030) & (USD Million)
Figure 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
Figure 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019-2030), (by Headquarter Location)
Figure 6. United States Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 7. China Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 8. Europe Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 9. Japan Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 10. South Korea Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 11. ASEAN Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 12. India Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 13. Hepatocellular Carcinoma Targeted Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 16. World Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share by Region (2019-2030)
Figure 17. United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 18. China Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 20. Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 21. South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 22. ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 23. India Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Producer Shipments of Hepatocellular Carcinoma Targeted Drug by Player Revenue ($MM) and Market Share (%): 2023
Figure 25. Global Four-firm Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug Markets in 2023
Figure 26. Global Four-firm Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug Markets in 2023
Figure 27. United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
Figure 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
Figure 30. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type in 2023
Figure 31. Sorafenib
Figure 32. Lenvatinib
Figure 33. Regorafenib
Figure 34. Other
Figure 35. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2019-2030)
Figure 36. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
Figure 37. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Application in 2023
Figure 38. Hospital
Figure 39. Retail Pharmacy
Figure 40. Other
Figure 41. Hepatocellular Carcinoma Targeted Drug Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
btl

Related Reports

shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

Page: 131

Published Date: 24 Feb 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

The global Hepatocellular Carcinoma Targeted Drug market size is expected to reach $ 1439.2 million by 2030, rising at a market growth of 7.5% CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).

This report studies the global Hepatocellular Carcinoma Targeted Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Hepatocellular Carcinoma Targeted Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hepatocellular Carcinoma Targeted Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Hepatocellular Carcinoma Targeted Drug total market, 2019-2030, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Hepatocellular Carcinoma Targeted Drug total market, key domestic companies and share, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug revenue by player and market share 2019-2024, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Type, CAGR, 2019-2030, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Hepatocellular Carcinoma Targeted Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma and CSPC, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hepatocellular Carcinoma Targeted Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Hepatocellular Carcinoma Targeted Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Type
Sorafenib
Lenvatinib
Regorafenib
Other

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Application
Hospital
Retail Pharmacy
Other

Companies Profiled:
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere

Key Questions Answered
1. How big is the global Hepatocellular Carcinoma Targeted Drug market?
2. What is the demand of the global Hepatocellular Carcinoma Targeted Drug market?
3. What is the year over year growth of the global Hepatocellular Carcinoma Targeted Drug market?
4. What is the total value of the global Hepatocellular Carcinoma Targeted Drug market?
5. Who are the major players in the global Hepatocellular Carcinoma Targeted Drug market?
btl

Table of Contents

1 Supply Summary
1.1 Hepatocellular Carcinoma Targeted Drug Introduction
1.2 World Hepatocellular Carcinoma Targeted Drug Market Size & Forecast (2019 & 2023 & 2030)
1.3 World Hepatocellular Carcinoma Targeted Drug Total Market by Region (by Headquarter Location)
1.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Region (2019-2030), (by Headquarter Location)
1.3.2 United States Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.3 China Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.4 Europe Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.5 Japan Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.6 South Korea Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.7 ASEAN Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.3.8 India Hepatocellular Carcinoma Targeted Drug Market Size (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Hepatocellular Carcinoma Targeted Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Hepatocellular Carcinoma Targeted Drug Major Market Trends

2 Demand Summary
2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region
2.2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2019-2024)
2.2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2025-2030)
2.3 United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.4 China Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.5 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.6 Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.7 South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.8 ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)
2.9 India Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030)

3 World Hepatocellular Carcinoma Targeted Drug Companies Competitive Analysis
3.1 World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2019-2024)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug in 2023
3.2.3 Global Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug in 2023
3.3 Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
3.4 Hepatocellular Carcinoma Targeted Drug Market: Overall Company Footprint Analysis
3.4.1 Hepatocellular Carcinoma Targeted Drug Market: Region Footprint
3.4.2 Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
3.4.3 Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
4.1.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
4.2 United States Based Companies VS China Based Companies: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison
4.2.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
4.3 United States Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2019-2024
4.3.1 United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)
4.4 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue and Market Share, 2019-2024
4.4.1 China Based Hepatocellular Carcinoma Targeted Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)
4.5 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2019-2024
4.5.1 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024)

5 Market Analysis by Type
5.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Sorafenib
5.2.2 Lenvatinib
5.2.3 Regorafenib
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2019-2024)
5.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2025-2030)
5.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
6.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2024)
6.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2025-2030)
6.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2030)

7 Company Profiles
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
7.1.4 Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Eisai
7.2.1 Eisai Details
7.2.2 Eisai Major Business
7.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
7.2.4 Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.2.5 Eisai Recent Developments/Updates
7.2.6 Eisai Competitive Strengths & Weaknesses
7.3 Zelgen
7.3.1 Zelgen Details
7.3.2 Zelgen Major Business
7.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
7.3.4 Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.3.5 Zelgen Recent Developments/Updates
7.3.6 Zelgen Competitive Strengths & Weaknesses
7.4 Cipla
7.4.1 Cipla Details
7.4.2 Cipla Major Business
7.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
7.4.4 Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.4.5 Cipla Recent Developments/Updates
7.4.6 Cipla Competitive Strengths & Weaknesses
7.5 Natco Pharma
7.5.1 Natco Pharma Details
7.5.2 Natco Pharma Major Business
7.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.5.4 Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.5.5 Natco Pharma Recent Developments/Updates
7.5.6 Natco Pharma Competitive Strengths & Weaknesses
7.6 BEACON Pharma
7.6.1 BEACON Pharma Details
7.6.2 BEACON Pharma Major Business
7.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.6.4 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.6.5 BEACON Pharma Recent Developments/Updates
7.6.6 BEACON Pharma Competitive Strengths & Weaknesses
7.7 Jiangxi Shanxiang
7.7.1 Jiangxi Shanxiang Details
7.7.2 Jiangxi Shanxiang Major Business
7.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
7.7.4 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.7.5 Jiangxi Shanxiang Recent Developments/Updates
7.7.6 Jiangxi Shanxiang Competitive Strengths & Weaknesses
7.8 Yao Pharma
7.8.1 Yao Pharma Details
7.8.2 Yao Pharma Major Business
7.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
7.8.4 Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.8.5 Yao Pharma Recent Developments/Updates
7.8.6 Yao Pharma Competitive Strengths & Weaknesses
7.9 CSPC
7.9.1 CSPC Details
7.9.2 CSPC Major Business
7.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
7.9.4 CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.9.5 CSPC Recent Developments/Updates
7.9.6 CSPC Competitive Strengths & Weaknesses
7.10 CHIATAI Tianqing
7.10.1 CHIATAI Tianqing Details
7.10.2 CHIATAI Tianqing Major Business
7.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
7.10.4 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.10.5 CHIATAI Tianqing Recent Developments/Updates
7.10.6 CHIATAI Tianqing Competitive Strengths & Weaknesses
7.11 Simcere
7.11.1 Simcere Details
7.11.2 Simcere Major Business
7.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
7.11.4 Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024)
7.11.5 Simcere Recent Developments/Updates
7.11.6 Simcere Competitive Strengths & Weaknesses

8 Industry Chain Analysis
8.1 Hepatocellular Carcinoma Targeted Drug Industry Chain
8.2 Hepatocellular Carcinoma Targeted Drug Upstream Analysis
8.3 Hepatocellular Carcinoma Targeted Drug Midstream Analysis
8.4 Hepatocellular Carcinoma Targeted Drug Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
Table 2. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
Table 3. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
Table 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019-2024), (by Headquarter Location)
Table 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2025-2030), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Hepatocellular Carcinoma Targeted Drug Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
Table 8. World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 9. World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2025-2030) & (USD Million)
Table 10. World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2019-2024) & (USD Million)
Table 11. Revenue Market Share of Key Hepatocellular Carcinoma Targeted Drug Players in 2023
Table 12. World Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Player, Based on Revenue in 2023
Table 13. Global Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
Table 14. Head Office of Key Hepatocellular Carcinoma Targeted Drug Player
Table 15. Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
Table 16. Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
Table 17. Hepatocellular Carcinoma Targeted Drug Mergers & Acquisitions Activity
Table 18. United States VS China Hepatocellular Carcinoma Targeted Drug Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 19. United States VS China Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 20. United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 22. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 23. China Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 25. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 26. Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2019-2024) & (USD Million)
Table 28. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2019-2024)
Table 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
Table 30. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2019-2024) & (USD Million)
Table 31. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2025-2030) & (USD Million)
Table 32. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
Table 33. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2019-2024) & (USD Million)
Table 34. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2025-2030) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
Table 38. Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Eisai Basic Information, Area Served and Competitors
Table 42. Eisai Major Business
Table 43. Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
Table 44. Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 45. Eisai Recent Developments/Updates
Table 46. Eisai Competitive Strengths & Weaknesses
Table 47. Zelgen Basic Information, Area Served and Competitors
Table 48. Zelgen Major Business
Table 49. Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
Table 50. Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 51. Zelgen Recent Developments/Updates
Table 52. Zelgen Competitive Strengths & Weaknesses
Table 53. Cipla Basic Information, Area Served and Competitors
Table 54. Cipla Major Business
Table 55. Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
Table 56. Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 57. Cipla Recent Developments/Updates
Table 58. Cipla Competitive Strengths & Weaknesses
Table 59. Natco Pharma Basic Information, Area Served and Competitors
Table 60. Natco Pharma Major Business
Table 61. Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 62. Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 63. Natco Pharma Recent Developments/Updates
Table 64. Natco Pharma Competitive Strengths & Weaknesses
Table 65. BEACON Pharma Basic Information, Area Served and Competitors
Table 66. BEACON Pharma Major Business
Table 67. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 68. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 69. BEACON Pharma Recent Developments/Updates
Table 70. BEACON Pharma Competitive Strengths & Weaknesses
Table 71. Jiangxi Shanxiang Basic Information, Area Served and Competitors
Table 72. Jiangxi Shanxiang Major Business
Table 73. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
Table 74. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 75. Jiangxi Shanxiang Recent Developments/Updates
Table 76. Jiangxi Shanxiang Competitive Strengths & Weaknesses
Table 77. Yao Pharma Basic Information, Area Served and Competitors
Table 78. Yao Pharma Major Business
Table 79. Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
Table 80. Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 81. Yao Pharma Recent Developments/Updates
Table 82. Yao Pharma Competitive Strengths & Weaknesses
Table 83. CSPC Basic Information, Area Served and Competitors
Table 84. CSPC Major Business
Table 85. CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
Table 86. CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 87. CSPC Recent Developments/Updates
Table 88. CSPC Competitive Strengths & Weaknesses
Table 89. CHIATAI Tianqing Basic Information, Area Served and Competitors
Table 90. CHIATAI Tianqing Major Business
Table 91. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
Table 92. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 93. CHIATAI Tianqing Recent Developments/Updates
Table 94. Simcere Basic Information, Area Served and Competitors
Table 95. Simcere Major Business
Table 96. Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
Table 97. Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
Table 98. Global Key Players of Hepatocellular Carcinoma Targeted Drug Upstream (Raw Materials)
Table 99. Hepatocellular Carcinoma Targeted Drug Typical Customers
List of Figure
Figure 1. Hepatocellular Carcinoma Targeted Drug Picture
Figure 2. World Hepatocellular Carcinoma Targeted Drug Total Market Size: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Hepatocellular Carcinoma Targeted Drug Total Market Size (2019-2030) & (USD Million)
Figure 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
Figure 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2019-2030), (by Headquarter Location)
Figure 6. United States Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 7. China Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 8. Europe Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 9. Japan Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 10. South Korea Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 11. ASEAN Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 12. India Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2019-2030) & (USD Million)
Figure 13. Hepatocellular Carcinoma Targeted Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 16. World Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share by Region (2019-2030)
Figure 17. United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 18. China Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 20. Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 21. South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 22. ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 23. India Hepatocellular Carcinoma Targeted Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Producer Shipments of Hepatocellular Carcinoma Targeted Drug by Player Revenue ($MM) and Market Share (%): 2023
Figure 25. Global Four-firm Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug Markets in 2023
Figure 26. Global Four-firm Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug Markets in 2023
Figure 27. United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2019 & 2023 & 2030)
Figure 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2019 & 2023 & 2030
Figure 30. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type in 2023
Figure 31. Sorafenib
Figure 32. Lenvatinib
Figure 33. Regorafenib
Figure 34. Other
Figure 35. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2019-2030)
Figure 36. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2019 & 2023 & 2030
Figure 37. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Application in 2023
Figure 38. Hospital
Figure 39. Retail Pharmacy
Figure 40. Other
Figure 41. Hepatocellular Carcinoma Targeted Drug Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
btl

Related Reports

jiaGou

Add To Cart

gouMai

Buy Now